LAANTERN: Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Study Details
Study Description
Brief Summary
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 1,000 patients and up to 50 sites.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Safety (Reportable adverse events) [up to 12 months]
Safety profile described by the NBS and surgical-related AEs
- Reason for NeuroBlate [Index procedure]
To identify the primary reason the NeuroBlate system was chosen for subject
- Number of patients demonstrating local control, overall survival, and seizure freedom (ENGEL and ILAE classifications) [up to 12 months or last follow-up]
Collected for all subjects by disease etiology. Local control as measured by time to local tumor recurrence. Overall survival assessed by Kaplan-Meier method. Seizure freedom assessed for all subjects with epilepsy at time of last follow-up. The ENGEL surgical outcome scale is composed of four classes of epilepsy (Class I, Class II, Class III, Class IV) categorized by severity. The ILAE outcome scale contains six classes (Class 1, 2, 3, 4, 5, 6) categorized by severity.
- Change in Quality of Life [up to 12 months or last follow-up]
Assessed by the following questionnaires: KPS (subjects with CNS malignancy): Scale ranged 0-100 measuring the ability of patients with cancer to perform ordinary daily activities FACT-Br (subjects with CNS malignancy): Measures general quality of life reflecting symptoms associated with brain malignancies across 5 scales (physical well-being social/family well-being, emotional well-being, functional well-being, and other) EQ-5D (all subjects): A generic measure of health consisting of the descriptive system and the visual analogue scale (VAS). The descriptive system assesses subject mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS reports the subject's self-rated health QOLIE-31 (subjects with epilepsy): Contains 7 scales assessing emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life for adults
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject or legally authorized representative provides written authorization and/or consent
-
Subject who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder
Exclusion Criteria:
-
Subject who is, or is expected to be inaccessible for follow-up
-
Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator, may prevent participation or otherwise render subject ineligibility for the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center | Phoenix | Arizona | United States | 85013 |
2 | University of Arkansas for Medical Sciences | Little Rock | Arkansas | United States | 72205 |
3 | University of California, San Diego | La Jolla | California | United States | 92093 |
4 | Children's Hospital of Orange County | Orange | California | United States | 92868 |
5 | Yale University School of Medicine | New Haven | Connecticut | United States | 06510 |
6 | Advent Health Orlando | Orlando | Florida | United States | 32804 |
7 | The Cleveland Clinic Florida | Weston | Florida | United States | 33331 |
8 | Northwestern University | Chicago | Illinois | United States | 60611 |
9 | University of Kansas Medical Center | Kansas City | Kansas | United States | 66160 |
10 | University of Louisville | Louisville | Kentucky | United States | 40208 |
11 | Norton Cancer Institute | Louisville | Kentucky | United States | 40241 |
12 | University of Minnesota | Minneapolis | Minnesota | United States | 55455 |
13 | United Children's Hospital St. Paul | Saint Paul | Minnesota | United States | 55102 |
14 | Washington University | Saint Louis | Missouri | United States | 63110 |
15 | New York University Langone Medical Center | New York | New York | United States | 10016 |
16 | Icahn School of Medicine at Mount Sinai | New York | New York | United States | 10029 |
17 | Weill Cornell Medicine | New York | New York | United States | 10065 |
18 | SUNY Upstate Medical University | Syracuse | New York | United States | 13210 |
19 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
20 | Wake Forest | Winston-Salem | North Carolina | United States | 27157 |
21 | University Hospitals Cleveland Medical Center | Cleveland | Ohio | United States | 44106 |
22 | Cleveland Clinic Foundation | Cleveland | Ohio | United States | 44195 |
23 | Geisinger Medical Center | Danville | Pennsylvania | United States | 17822 |
24 | Thomas Jefferson University | Philadelphia | Pennsylvania | United States | 19107 |
25 | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | United States | 15213 |
26 | Saint Thomas West Hospital and Research Institute | Nashville | Tennessee | United States | 37205 |
27 | University of Texas Southwestern Medical Center | Dallas | Texas | United States | 75390 |
28 | MD Anderson | Houston | Texas | United States | 77030 |
29 | University of British Columbia | Vancouver | British Columbia | Canada | V5Z 1M9 |
Sponsors and Collaborators
- Monteris Medical
Investigators
- Principal Investigator: Eric Leuthardt, MD, Washington University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LAANTERN